A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: typepotentialto complyable tochildbearing
  Phrases that lowered it: healthysubjectsproductformulationinvestigate the
• Sponsor's past termination rate: 15% (raises risk) · Sponsor's track record
• Primary purpose: not given (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 384 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 740 (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 75 (raises risk) · Who can join
• Keywords listed: 1 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation NCT02006277 · started 2013 · scored riskier than 2% of active trials completed
• Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants NCT03978143 · started 2019 · scored riskier than 3% of active trials completed
• A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers NCT01168934 · started 2010 · scored riskier than 3% of active trials completed
• Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule NCT01297595 · started 2011 · scored riskier than 3% of active trials completed
• Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) NCT04856293 · started 2021 · scored riskier than 2% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.